Zenith Drugs Peer Comparison

NSE: ZENITHDRUG

₹44.35

₹3.15 (7.65%)

As on 28-Aug-2026IST

Market cap

₹76 Cr

Revenue (TTM)

₹133 Cr

P/E Ratio

19.3

P/B Ratio

1.1

Div. Yield

0 %

Edit

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	76	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	133	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	7.16	1,018.97	497.77	603.02	270.18
Net Margin (%)	5.27	10.47	20.72	22.63	23.29
RoE (%)	10.88	21.30	28.49	19.61	14.45
Price to Earnings	19.29	35.10	59.86	27.51	56.31
Price-To-Book	1.10	6.77	14.74	4.76	7.48

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	133.32	7,896.00	1,476.84	2,386.88	1,200.09
Total Income	135.93	7,968.78	1,497.35	2,421.45	1,244.53
Total Expenditure	119.49	6,427.14	1,153.58	1,704.30	693.24
EBITDA	13.83	1,468.85	323.26	682.58	506.84
Depreciation	2.97	384.13	65.55	60.61	54.37
EBIT	10.86	1,084.73	257.71	621.98	452.47
Interest	3.96	175.78	8.30	2.41	1.04
Other Income	2.61	72.79	20.51	34.57	44.45
Exceptional Items	-0.25	-10.38	76.40	--	--
Profit before Tax	9.26	971.35	346.33	654.13	494.55
Provision for Tax	2.10	263.88	86.22	168.50	122.91
Profit after Tax	7.16	707.47	260.11	485.63	371.64

Liabilities (₹ Cr)

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	69.38	4,446.19	1,524.81	2,817.37	1,812.72
Minority Interest	--	195.37	--	--	--
Non-Current Liabilities	12.78	811.91	189.39	466.05	37.47
Current Liabilities	79.30	2,668.27	465.69	470.16	184.06
Total Liabilities	161.48	8,121.73	2,179.88	3,753.59	2,034.25

Assets (₹ Cr)

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	46.29	3,565.87	1,040.38	1,418.43	899.01
Current Assets	115.18	4,555.86	1,139.50	2,335.16	1,135.24
Total Assets	161.48	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	48.57	730.70	136.01	0.00	0.38
Net Current Assets	35.87	1,887.59	673.81	1,865.00	951.18
Contingent Liabilities	12.82	393.94	8.97	4.82	3.91

Cashflow (₹ Cr)

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-5.47	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-31.41	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	28.39	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	-8.48	-56.25	44.21	-230.35	-14.24

Ratios

Profitability Ratios

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	12.96	22.49	23.45	25.50	29.62
ROE (%)	10.88	19.19	18.54	18.94	22.26
ROA (%)	4.85	8.94	12.97	13.34	19.90
EBIT Margin (%)	12.33	19.52	23.28	30.05	45.94
Net Margin (%)	5.27	8.88	17.37	20.06	29.86
Cash Profit Margin (%)	6.67	13.61	22.05	22.79	35.50

Growth Ratios

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	1.29	18.59	-5.24	4.54	18.01
EBIT Growth (%)	-14.17	19.81	-27.65	4.50	18.31
Net Profit Growth (%)	-24.92	34.10	-13.32	3.13	20.62
EPS Growth (%)	-24.92	30.75	-13.32	3.12	20.62
Book Value Growth (%)	11.51	50.94	18.89	20.94	18.74

Valuation Ratios

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	17.17	29.84	59.57	27.24	47.19
Price / Book Value	1.77	4.58	10.17	4.71	9.67
Dividend Yield (%)	0.00	0.28	0.10	0.46	0.64
EV/EBITDA	10.42	13.55	44.72	18.35	31.81
Market Cap (₹ Cr)	122.96	20,327.45	15,494.53	13,228.83	17,537.35

Solvency Ratios

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.70	0.16	0.09	0.00	0.00
Short term debt to equity ratio	0.44	0.11	--	--	0.00
Current Ratio	1.45	1.71	2.45	4.97	6.17
Quick Ratio	0.95	0.98	1.62	3.53	4.87
Interest Coverage	3.34	6.53	42.74	271.97	475.76

Operating Efficiency Ratios

	Zenith Drugs	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	45.44	25.36	21.38	40.63	43.47
Asset Turnover	1.03	1.01	0.74	0.66	0.64
Receivable days	153.74	87.83	85.17	132.12	132.49
Inventory Days	78.54	78.64	90.97	102.08	68.07
Payable days	238.18	174.97	137.94	133.54	123.94
Cash Conversion Cycle	-5.90	-8.50	38.21	100.66	76.63